Logo image of BHC.CA

BAUSCH HEALTH COS INC (BHC.CA) Stock Price, Forecast & Analysis

Canada - Toronto Stock Exchange - TSX:BHC - CA0717341071 - Common Stock

9.53 CAD
-0.06 (-0.63%)
Last: 12/31/2025, 7:00:00 PM

BHC.CA Key Statistics, Chart & Performance

Key Statistics
Market Cap3.53B
Revenue(TTM)10.03B
Net Income(TTM)362.00M
Shares370.85M
Float325.39M
52 Week High11.97
52 Week Low5.91
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)5.23
PE1.82
Fwd PE1.62
Earnings (Next)02-17 2026-02-17/amc
IPO1994-09-20
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


BHC.CA short term performance overview.The bars show the price performance of BHC.CA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 1 -1 2 -2 -3

BHC.CA long term performance overview.The bars show the price performance of BHC.CA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 5 -5 10 -10 -15

The current stock price of BHC.CA is 9.53 CAD. In the past month the price decreased by -3.54%. In the past year, price decreased by -15.36%.

BAUSCH HEALTH COS INC / BHC Daily stock chart

BHC.CA Competitors/Peers

The largest stocks on the Canadian markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
TLRY.CA TILRAY BRANDS INC N/A 1.44B
CRON.CA CRONOS GROUP INC 24 1.38B
DHT-UN.CA DRI HEALTHCARE TRUST 7.14 885.62M
GUD.CA KNIGHT THERAPEUTICS INC N/A 600.70M
WEED.CA CANOPY GROWTH CORP N/A 574.80M
NGEN.CA NERVGEN PHARMA CORP N/A 564.94M
CPH.CA CIPHER PHARMACEUTICALS INC 16.73 382.07M
TSND.CA TERRASCEND CORP N/A 364.57M
ACB.CA AURORA CANNABIS INC N/A 324.39M
HITI.CA HIGH TIDE INC N/A 320.21M
OGI.CA ORGANIGRAM GLOBAL INC N/A 310.30M
XLY.CA AUXLY CANNABIS GROUP INC 3.62 195.52M

About BHC.CA

Company Profile

BHC logo image Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. The company is headquartered in Laval, Quebec and currently employs 20,700 full-time employees. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.

Company Info

BAUSCH HEALTH COS INC

2150 St. Elzear Blvd. West

Laval QUEBEC H7L 4A8 CA

CEO: Joseph C. Papa

Employees: 20700

BHC Company Website

BHC Investor Relations

Phone: 18003611448

BAUSCH HEALTH COS INC / BHC.CA FAQ

What does BAUSCH HEALTH COS INC do?

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. The company is headquartered in Laval, Quebec and currently employs 20,700 full-time employees. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.


Can you provide the latest stock price for BAUSCH HEALTH COS INC?

The current stock price of BHC.CA is 9.53 CAD. The price decreased by -0.63% in the last trading session.


What is the dividend status of BAUSCH HEALTH COS INC?

BHC.CA does not pay a dividend.


How is the ChartMill rating for BAUSCH HEALTH COS INC?

BHC.CA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


On which exchange is BHC.CA stock listed?

BHC.CA stock is listed on the Toronto Stock Exchange exchange.


What sector and industry does BAUSCH HEALTH COS INC belong to?

BAUSCH HEALTH COS INC (BHC.CA) operates in the Health Care sector and the Pharmaceuticals industry.


BHC.CA Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to BHC.CA. When comparing the yearly performance of all stocks, BHC.CA is a bad performer in the overall market: 81.42% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BHC.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to BHC.CA. While BHC.CA is still in line with the averages on profitability rating, there are concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BHC.CA Financial Highlights

Over the last trailing twelve months BHC.CA reported a non-GAAP Earnings per Share(EPS) of 5.23. The EPS increased by 1.33% compared to the year before.


Industry RankSector Rank
PM (TTM) 3.61%
ROA 1.35%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%2.65%
Sales Q2Q%6.81%
EPS 1Y (TTM)1.33%
Revenue 1Y (TTM)5.86%

BHC.CA Forecast & Estimates

9 analysts have analysed BHC.CA and the average price target is 10.2 CAD. This implies a price increase of 7.03% is expected in the next year compared to the current price of 9.53.

For the next year, analysts expect an EPS growth of 5.32% and a revenue growth 6.13% for BHC.CA


Analysts
Analysts48.89
Price Target10.2 (7.03%)
EPS Next Y5.32%
Revenue Next Year6.13%

BHC.CA Ownership

Ownership
Inst Owners45.78%
Ins Owners10.79%
Short Float %N/A
Short RatioN/A